258 related articles for article (PubMed ID: 29171409)
1. A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy.
Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Nishigori C
Eur J Dermatol; 2018 Feb; 28(1):115-116. PubMed ID: 29171409
[No Abstract] [Full Text] [Related]
2. Pegylated interferon-α2b for local control of Langerhans cell sarcoma.
Ishitsuka Y; Iwamoto K; Oya K; Nakamura Y; Watanabe R; Okiyama N; Fujisawa Y; Fujimoto M
Eur J Dermatol; 2018 Dec; 28(6):835-836. PubMed ID: 30355544
[No Abstract] [Full Text] [Related]
3. Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?
Sondak VK; Flaherty LE
Lancet; 2008 Jul; 372(9633):89-90. PubMed ID: 18620932
[No Abstract] [Full Text] [Related]
4. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
6. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant interferon therapy for malignant melanoma: the debate.
Zhou Q; Zhang XS
Chin J Cancer; 2010 Nov; 29(11):907-13. PubMed ID: 20979689
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
10. Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).
Busse A; Rapion J; Fusi A; Suciu S; Nonnenmacher A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
Cancer Immunol Immunother; 2013 Jul; 62(7):1223-33. PubMed ID: 23624802
[TBL] [Abstract][Full Text] [Related]
11. How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
Tarhini AA; Kirkwood JM
J Clin Oncol; 2012 Nov; 30(31):3773-6. PubMed ID: 23008298
[No Abstract] [Full Text] [Related]
12. [Current aspects of adjuvant therapy of malignant melanoma].
Kähler KC; Egberts F; Hauschild A
Hautarzt; 2010 Jun; 61(6):523-31; quiz 532-3. PubMed ID: 20512304
[TBL] [Abstract][Full Text] [Related]
13. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Mozzillo N; Ascierto P
Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
[TBL] [Abstract][Full Text] [Related]
14. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon alph-2b (Sylatron) for melanoma.
Med Lett Drugs Ther; 2011 Sep; 53(1373):76. PubMed ID: 21921873
[No Abstract] [Full Text] [Related]
16. Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature.
Lawson BO; Khong HT
Anticancer Res; 2017 Mar; 37(3):1365-1368. PubMed ID: 28314304
[TBL] [Abstract][Full Text] [Related]
17. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
[TBL] [Abstract][Full Text] [Related]
18. Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients.
Schmittel A; Proebstle T; Engenhart-Cabillic R; Scheibenbogen C; Geueke AM; Thiel E; Keilholz U
Eur J Cancer; 2003 Mar; 39(4):476-80. PubMed ID: 12751378
[TBL] [Abstract][Full Text] [Related]
19. An update on pegylated IFN-α2b for the adjuvant treatment of melanoma.
Agarwala SS
Expert Rev Anticancer Ther; 2012 Nov; 12(11):1449-59. PubMed ID: 23249109
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]